GU Cancers 2019 | Pembrolizumab monotherapy and pembro-axitinib for RCC

Michael Atkins

Speaking from the 2019 Genitourinary Cancers Symposium, held in San Francisco, CA, Michael Atkins, MD, of Georgetown University, Washington, DC, discusses the promising results from the Phase II KEYNOTE-427 study with pembrolizumab (NCT02853344), and the Phase III KEYNOTE-426 trial (NCT02853331) looking at the combination of pembrolizumab with axitinib for treating advanced renal cell carcinoma (RCC).

Share this video